Promoter Ravi Agrawal has reported the creation and subsequent release of a pledge involving 5,33,333 equity shares of Ajanta Pharma Limited, both occurring on March 17, 2026. The initial creation of the pledge was for the purpose of Re-Financing activities. The corresponding release was attributed to an Excess Pledge situation. The disclosures were made to the stock exchanges on March 19, 2026, accompanied by the required regulatory filings.
Promoter Pledge Activity Disclosure
Ravi Agrawal, acting as a promoter and trustee for the Ravi Agrawal Trust, formally informed the stock exchanges on March 19, 2026, regarding significant changes in the encumbrance status of his holdings in Ajanta Pharma Limited.
The disclosure details the following key transactions, both executed on March 17, 2026:
- Pledge Creation: A pledge was created covering 5,33,333 equity shares of the company. The stated reason for this creation was Re-Financing.
- Pledge Release: Simultaneously, a release was executed for an equivalent number of 5,33,333 equity shares. The rationale provided for this release was due to Excess Pledge conditions being met.
Detailed Transaction Breakdown (Ravi Agrawal Trust)
The detailed filing provided specific figures related to the Ravi Agrawal Trust’s holdings and the movements:
Ravi P Agrawal, trustee for Ravi Agrawal Trust, reported 6,063,920 shares (4.85% stake) initially encumbered. Following the pledge creation:
- Creation Impact: An entry shows a Pledge Creation of 6,063,920 shares (4.85% stake), which was utilized for Business Financing with Bajaj Finance Limited (DP: Julis Bayer). This resulted in a post-event holding of 6,404,491 shares (5.13% stake) remaining pledged under a different entry, suggesting multiple transactions covered in the net figure.
- Release Impact: An entry shows a Pledge Release of 6,256,682 shares (5.01% stake), which was also linked to Business Financing.
The filing confirms that the promoter’s total reported holding prior to these specific transactions involved various entities, totaling significant ownership in the target company.
Regulatory Compliance Note
The announcement included the required prescribed forms under Regulation 31(1) and 31(2) of the applicable regulations, confirming full disclosure of the creation and release events on the shares of Ajanta Pharma Limited.
Source: BSE
